Clinical Trial of TQB2858 Injection in the Treatment of Advanced High-grade Sarcoma

NCT ID: NCT05262101

Last Updated: 2024-01-22

Basic Information

• Recruitment Status: TERMINATED
• Clinical Phase: PHASE2
• Total Enrollment: 7 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2022-05-09
• Study Completion Date: 2023-11-30

Brief Summary

This study is a single-arm, open-label, multicenter Phase Ib clinical trial evaluating TQB2858 injection in the treatment of advanced high-grade sarcoma. To evaluate the preliminary efficacy and safety of TQB2858 injection in patients with advanced high-grade sarcoma, and to explore the relevant biomarkers of TQB2858 injection.

Conditions

Advanced High-grade Sarcoma

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

TQB2858 injection

TQB2858 injection (1800mg intravenous(iv), on day 1 of every 3 weeks)

Group Type: EXPERIMENTAL

TQB2858 injection

Intervention Type: DRUG

TQB2858 is a dual-function fusion protein that is aProgrammed cell death 1 ligand 1 (PD-L1)/transforming growth factor-β(TGF-β) double antibody.

Interventions

TQB2858 injection

TQB2858 is a dual-function fusion protein that is aProgrammed cell death 1 ligand 1 (PD-L1)/transforming growth factor-β(TGF-β) double antibody.

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

• 1 Histologically confirmed unresectable, recurrent or metastatic high-grade sarcoma;
• 2 Received at least first-line therapy before, disease progression or intolerance during treatment, or disease progression after treatment; (excluding alveolar soft tissue sarcoma and clear cell sarcoma)

1. Cohort 1: newly treated acinar soft tissue sarcoma;

2. Cohort 2: Acinar soft tissue sarcoma with failed PD-1 therapy;

3. Cohort 3: Other subtypes (pleomorphic sarcoma, classic osteosarcoma, Ewing sarcoma, chondrosarcoma, dedifferentiated liposarcoma, etc.).

• 3 Age: 18 to 70 years old;
• 4 The Eastern Cooperative Oncology Group (ECOG) score: 0 to 1;
• 5 The expected survival period is ≥3 months;
• 6 Normal function of major organs
• 7 Women of childbearing age should agree to use effective contraceptive measures during the study period and 6 months after the end of the study, and have a negative serum or urine pregnancy test within 7 days before enrollment in the study; men should agree to use effective contraception during the study period and after the end of the study period 6 Effective contraceptive measures must be used within one month.
• 8 Patients voluntarily enroll in this study, sign an informed consent form and comply well.

Exclusion Criteria

• 1 Combined diseases and medical history:

1. Have presented with or currently have concurrent other malignancies within 2 years.

2. Unresolved toxic reactions due to any prior treatment above Common Terminology Criteria for Adverse Events (CTCAE) grade 1, excluding alopecia, peripheral sensory nerve disorders.

3. Major surgical treatment or significant traumatic injury within 28 days prior to the start of study treatment.

4. Long-term untreated wounds or fractures.

5. An arterial/venous thrombotic event within 6 months, such as cerebrovascular accident, deep vein thrombosis and pulmonary embolism.

6. Persons with a history of psychotropic substance abuse who are unable to abstain or have a mental disorder.

7. Subjects with any severe and/or uncontrollable disease, including:

• 2 Tumor-related symptoms and treatment:

1. Received surgery, chemotherapy, radiotherapy, or other anticancer therapy within 4 weeks prior to the start of study treatment;

2. Treatment with proprietary Chinese medicines with clear antitumor indications in the National Medical Products Administration (NMPA)-approved drug formulary within 2 weeks prior to the start of study treatment.

3. Uncontrolled pleural effusions, pericardial effusions, or ascites that still require repeated drainage;

4. Brain metastases with less than 4 weeks of stable symptom control after discontinuation of dehydrating agents and steroids.

• 3 Research and treatment related:

1. History of live attenuated vaccination within 28 days prior to the start of study treatment.

2. Prior history of severe allergy to macromolecular drugs or allergy to known components of TQB2858 injection.

3. Active autoimmune disease requiring systemic therapy that occurred within 2 years prior to the start of study treatment.

4. Diagnosis of immunodeficiency or being treated with systemic glucocorticoids or any other form of immunosuppressive therapy.

• 4 Participation in other clinical trials of antineoplastic drugs within 4 weeks prior to enrollment.
• 5 Subjects who, in the judgment of the investigator, have a concomitant illness that seriously jeopardizes the safety of the subject or interferes with the completion of the study, or for whom other reasons are deemed to exist for ineligibility for enrollment.

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 70 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Locations

Peking University People's Hospital

Beijing, Beijing Municipality, China

Countries

China

Other Identifiers

TQB2858-Ib-02

Identifier Type: -

Identifier Source: org_study_id